	US 12,152,059 B2
	Method of treating nash using a long-acting mutant human fibroblast growth factor
Jian Li, Tianjin (CN); Jun Han, Tianjin (CN); Xiaohui Ma, Tianjin (CN); Ping Tai, Tianjin (CN); Genbei Wang, Tianjin (CN); Xiaodan Cao, Tianjin (CN); Ruijing Huang, Tianjin (CN); Yongjie Jin, Tianjin (CN); Jing Li, Tianjin (CN); Chen Chen, Tianjin (CN); Guoyong Jia, Tianjin (CN); and Yuanyuan Wang, Tianjin (CN)
Assigned to TASLY BIOPHARMACEUTICALS CO., LTD., Shanghai (CN)
Filed by TASLY BIOPHARMACEUTICALS CO., LTD., Shanghai (CN)
Filed on Jul. 23, 2019, as Appl. No. 16/520,053.
Application 16/520,053 is a continuation in part of application No. PCT/CN2018/079482, filed on Mar. 19, 2018.
Claims priority of application No. 201710172824.0 (CN), filed on Mar. 22, 2017.
Prior Publication US 2019/0367574 A1, Dec. 5, 2019
Int. Cl. C07K 14/50 (2006.01); A61K 38/00 (2006.01); A61K 38/18 (2006.01); A61P 1/16 (2006.01)

CPC C07K 14/50 (2013.01) [A61P 1/16 (2018.01); A61K 38/00 (2013.01); A61K 38/1825 (2013.01)]

8 Claims

1. A method of treating non-alcoholic steatohepatitis (NASH), comprising administering a pharmaceutical composition comprising mPEG-CH₂—N^αH-mFGF21 or a pharmaceutically acceptable salt thereof as a water injection to a subject having NASH in an amount of 0.125 mg/kg/day or 2 mg/kg/day, wherein mFGF21 consists of SEQ ID NO: 1, and wherein the method improves lobular inflammation.